GLP-1 Overdose in America 2026
The GLP-1 overdose crisis in America has quietly escalated alongside the explosive popularity of weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro, and Zepbound. What began as a celebrated medical breakthrough — a class of drugs that genuinely helps millions manage obesity and type 2 diabetes — has created an entirely new and fast-growing public health challenge. As GLP-1 prescriptions in the US climbed from under 3% of adults in 2021 to nearly 13% by 2026, according to Epic Research, the number of people calling poison control centers because of GLP-1 overdose in the United States has surged at an almost unbelievable rate. The sheer accessibility of these medications, combined with a booming market for compounded, unregulated versions sold online, has left a large and growing number of Americans vulnerable to accidental and intentional overdoses.
What makes the 2026 GLP-1 overdose data particularly striking is the breadth of people affected — from adults taking slightly too high a dose to children accessing a parent’s injection pen out of curiosity. The US National Poison Data System (NPDS), maintained by America’s Poison Centers, has tracked this problem in real time, and the numbers are alarming. Poison centers across all 50 states are fielding record call volumes tied to these drugs, hospitalizations are rising, and federal agencies like the FDA have been forced to issue repeated safety warnings about compounded versions of semaglutide and tirzepatide. The data presented in this article draws exclusively from US government and government-affiliated public health sources, including the NPDS, the FDA, the CDC’s National Center for Health Statistics (NCHS), and the CalPoison (California Poison Control System) — because when it comes to understanding a public health emergency, only verified facts matter.
Key Interesting Facts: GLP-1 Overdose in the US 2026
GLP-1 OVERDOSE — FAST FACTS AT A GLANCE (US, 2026)
=====================================================
Poison Control Calls Since 2019
▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓ +1,500%
Total Cases (2019–2025)
▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓ ~23,000
Jan–Apr 2025 Cases Alone
▓▓▓▓▓▓▓▓▓▓▓▓▓▓ 3,633
Exposure Rate Increase (2017–2024)
▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓ +1,831%
Children (6–17) Exposure Rate Increase
▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓ +4,805%
| Fact | Data Point |
|---|---|
| % increase in poison control calls since 2019 | ~1,500% |
| Total GLP-1 exposure cases reported to US poison centers (2019–2025) | ~23,000 |
| GLP-1 exposure cases managed Jan–Apr 30, 2025 alone | 3,633 |
| Total single-substance GLP-1 exposures reported to NPDS (2017–2024) | 13,924 |
| Rate of exposures per million US population increase (2017–2024) | +1,830.8% (0.97 → 18.79 per million) |
| Rate increase among children aged 6–17 (2017–2024) | +4,805% (0.04 → 1.97 per million) |
| Cases with no or mild effects (2017–2024 NPDS data) | 91.7% |
| Cases with moderate effects | 8.0% |
| Cases with major effects | 42 exposures |
| Deaths recorded (NPDS 2017–2024) | 2 |
| GLP-1 exposures reported in 2016 (first tracked year) | 241 |
| GLP-1 exposures reported in 2022 | 2,170 |
| GLP-1 exposure cases nationally in 2020 | 1,090 |
| GLP-1 exposure cases nationally in 2024 | 8,501 |
| FDA adverse event reports for compounded semaglutide & tirzepatide (as of July 31, 2025) | 1,150 |
| Overdose cases in Washington State doubling period | Since 2024 |
| Indiana Poison Center GLP-1 calls in 2022 | 64 |
| Indiana Poison Center GLP-1 calls in 2025 | 320 |
| Proportion of Indiana cases involving women | 76% |
| Proportion of Indiana cases NOT requiring a healthcare facility visit | 73% |
| NJ Poison Control GLP-1 cases in 2021 | 29 |
| NJ Poison Control GLP-1 cases in 2024 | 189 |
| California CalPoison GLP-1 cases (2017–Dec 2023) | 1,047 |
| California cases requiring hospitalization | 266 (of 1,047) |
| California cases requiring critical care | 14 |
| Share of CA cases arriving after FDA’s 2021 Wegovy approval | ~78% |
| GLP-1 prescriptions for weight loss growth (2021–2026) | Quadrupled (under 3% → ~13%) |
Source: National Poison Data System (NPDS) — America’s Poison Centers; FDA; California Poison Control System (CalPoison)
The numbers in the table above are not just statistics — they represent a genuine and rapidly intensifying public health emergency unfolding across every US state in 2026. The 1,500% rise in GLP-1 poison control calls since 2019 tracks almost precisely with the rise in prescriptions, and the trajectory shows no sign of leveling off. What is most sobering about these figures is that they almost certainly represent a significant undercount — as confirmed by toxicologists cited in NPDS research — because many individuals who overdose simply manage their symptoms at home without ever contacting a poison center or emergency room. Only 8.3% of all recorded cases resulted in moderate or greater medical effects, but as the raw case count balloons past tens of thousands nationally, even that relatively small percentage translates to hundreds of Americans each year facing serious medical consequences.
The fact that 91.7% of overdose cases produce no or mild effects might seem reassuring, but it can create a false sense of safety in the public mind. The two recorded deaths in the NPDS dataset from 2017 to 2024 confirm that fatal GLP-1 overdose in the US is a documented reality, not a hypothetical. The staggering 4,805% increase in exposure rates among children aged 6–17 is perhaps the most urgent signal of all — children are accessing these drugs in the home, largely because parents are not securing their medications properly, and the consequences can be serious and prolonged, given that GLP-1 medications remain active in the body for up to a week after a single dose.
GLP-1 Overdose Exposure Growth by Year in the US 2026
ANNUAL GLP-1 POISON CENTER EXPOSURE CASES — US (2016–2024)
============================================================
2016 |▓ | 241
2017 |▓▓ | ~1,400 (rate: 0.97/M)
2020 |▓▓▓▓▓▓▓▓▓▓ | 1,090
2021 |▓▓▓▓▓▓▓▓▓▓▓▓▓ | ~1,500 (rate: 3.49/M)
2022 |▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓ | 2,170
2024 |▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓ | 8,501
============================================================
Rate per million population (2024): 18.79
| Year | Annual GLP-1 Exposure Cases (National NPDS) | Rate per Million US Population |
|---|---|---|
| 2016 | 241 | N/A (first tracked year) |
| 2017 | ~1,400 (single-substance baseline) | 0.97 |
| 2020 | 1,090 | N/A |
| 2021 | ~1,500 | 3.49 |
| 2022 | 2,170 | 6.32 |
| 2024 | 8,501 | 18.79 |
| Jan–Apr 2025 | 3,633 (partial year) | Annualizing to 10,000+ |
Source: National Poison Data System (NPDS), America’s Poison Centers; Journal of Medical Toxicology (2024 peer-reviewed NPDS analysis)
The year-over-year trajectory of GLP-1 exposure cases in the United States is one of the steepest growth curves in recent poison control history. The jump from 1,090 cases in 2020 to 8,501 cases in 2024 — nearly an eightfold increase in just four years — maps directly onto the explosion of GLP-1 prescriptions following the FDA’s landmark approval of Wegovy (semaglutide) for obesity in June 2021. Before that approval, GLP-1 drugs were used primarily to treat type 2 diabetes in a more medically supervised setting. After 2021, the market opened up dramatically, bringing in millions of new patients with varying levels of medical literacy, supervision, and access to proper dosing equipment. The 2022 data point is particularly instructive: that single year saw an 80.9% increase in the exposure rate from 2021, confirming that the crisis accelerated almost immediately after widespread obesity-indication approvals.
The partial-year figure of 3,633 cases between January and April 30, 2025 alone puts the annualized 2025 total on pace to far exceed 2024’s 8,501 cases. Experts at America’s Poison Centers have confirmed this upward trend is expected to continue as long as prescription rates keep rising and compounded GLP-1 products remain in circulation. The rate of 18.79 cases per million US population in 2024 — up from just 0.97 in 2017 — represents a systemic public health shift, not a random statistical blip. This data makes the case that GLP-1 overdose has become a mainstream medical concern in the US, requiring urgent attention from clinicians, pharmacists, regulators, and patients alike.
GLP-1 Overdose Demographics: Who Is Affected in the US 2026
GLP-1 OVERDOSE — DEMOGRAPHICS BREAKDOWN (US, 2024–2025)
=========================================================
BY GENDER (Indiana Poison Center, 2025):
Women ▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓ 76%
Men ▓▓▓▓▓▓▓▓▓▓ 24%
BY OUTCOME (NPDS 2017–2024):
No/Mild Effect ▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓ 91.7%
Moderate ▓▓ 8.0%
Major ▓ 0.3%
BY HEALTHCARE FACILITY NEED (Indiana, 2025):
Managed at home ▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓ 73%
Required care ▓▓▓▓▓ 27%
| Demographic Category | Data | Source |
|---|---|---|
| Cases involving women (NPDS 2017–2022 study) | 71.3% | NPDS / Journal of Medical Toxicology |
| Cases involving women (Indiana Poison Center, 2025) | 76% | Indiana Poison Center |
| Cases attributable to therapeutic errors (NPDS 2017–2022) | 79.9% | NPDS |
| Cases evaluated at a healthcare facility (NPDS 2017–2022) | 22.4% | NPDS |
| Cases admitted to critical care unit | 0.9% | NPDS |
| Cases admitted to non-critical care unit | 4.1% | NPDS |
| Serious medical outcomes (NPDS 2017–2022) | 6.2% | NPDS |
| Indiana cases NOT requiring a health facility (2025) | 73% | Indiana Poison Center |
| Exposure rate increase among children 6–17 (2017–2024) | +4,805% | NPDS |
| Children 6–17 more likely to have intentional misuse exposure | Yes — higher rate than adults | NPDS/Journal of Medical Toxicology |
| Children 12–17 more likely to experience serious medical outcome vs adults | Yes — confirmed | NPDS |
| Most common symptom in all age groups | Nausea, vomiting, dizziness | CalPoison, NPDS |
Source: National Poison Data System (NPDS); Indiana Poison Center; California Poison Control System (CalPoison)
The demographic profile of GLP-1 overdose victims in the US is telling in several important ways. Women account for the substantial majority of cases — 71.3% to 76% depending on the data source — which reflects both the higher prevalence of GLP-1 prescriptions among women seeking weight-loss treatment and the demographic composition of who is most aggressively marketed these drugs. The 79.9% rate of therapeutic errors as the cause of overdose is critical context: the vast majority of people calling poison control centers did not intentionally take too much. They accidentally doubled a dose, took doses too close together, or drew the wrong amount from a multi-dose vial — exactly the kinds of mistakes that happen when patients are given complex, self-administered injectable medications without adequate education and follow-up from their healthcare providers.
The pediatric data is the most alarming dimension of the 2026 GLP-1 overdose landscape. A 4,805% increase in exposure rates among children 6–17 between 2017 and 2024 is a number that demands immediate attention from parents and caregivers. Research published in the Journal of Medical Toxicology and based on NPDS data from 2017–2024 confirmed that children aged 12–17 are more likely than adults to experience a serious medical outcome from GLP-1 exposure, and children are more likely to have exposures classified as intentional misuse — suggesting that some older children and teenagers may be deliberately experimenting with or taking these medications for weight loss without medical guidance. The case of 7-year-old Jessa Milender, who accidentally injected herself with her mother’s Mounjaro pen in December 2024 and required repeated hospitalization, is a documented and widely reported example of the pediatric risk that these statistics represent.
State-Level GLP-1 Overdose Data in the US 2026
STATE-LEVEL GLP-1 POISON CONTROL CALL GROWTH
=============================================
Indiana (2022 → 2025):
2022 |▓▓▓▓▓ | 64 calls
2024 |▓▓▓▓▓▓▓▓▓▓ | 153 calls
2025 |▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓ | 320 calls
New Jersey (2021 → 2024):
2021 |▓▓ | 29 cases
2024 |▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓ | 189 cases
CHOP Poison Control, PA (2023 → 2024 → early 2025):
2023 |▓▓▓▓▓▓▓▓▓▓ | 95 cases
2024 |▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓| 192 cases
2025* |▓▓▓▓▓▓▓▓▓▓▓▓▓▓ | 126 cases (partial year)
| State / Region | Year | GLP-1 Poison Control Cases | Notable Trend |
|---|---|---|---|
| Indiana (statewide) | 2022 | 64 | — |
| Indiana (statewide) | 2024 | 153 | — |
| Indiana (statewide) | 2025 | 320 | Doubled year-over-year |
| New Jersey | 2021 | 29 | — |
| New Jersey | 2024 | 189 | +552% in 3 years |
| CHOP (Children’s Hospital of Philadelphia area) | 2023 | 95 | — |
| CHOP (PA) | 2024 | 192 | Doubled year-over-year |
| CHOP (PA) | Early 2025 | 126 (partial year) | On pace to exceed 2024 |
| California (CalPoison) | 2017–Dec 2023 | 1,047 total | ~78% after 2021 Wegovy approval |
| California | Hospitalizations | 266 of 1,047 | 25.4% hospitalization rate |
| California | Critical care admissions | 14 | Of 266 hospitalized cases |
| Washington State | 2024–2026 | Doubled since 2024 | Ongoing rapid increase |
Source: Indiana Poison Center; New Jersey Poison Control Center; Children’s Hospital of Philadelphia Poison Control Center; California Poison Control System (CalPoison); America’s Poison Centers
The state-level GLP-1 overdose data in the US paints a consistent picture from coast to coast: every state that has released granular figures is showing steep and accelerating increases. Indiana’s jump from 64 calls in 2022 to 320 calls in 2025 — a 400% increase — mirrors the national trend, and the doubling between 2024 and 2025 alone suggests the crisis is still in a high-growth phase, not yet approaching a plateau. What is also notable about the Indiana data is that 76% of cases involve adult women, reinforcing the national NPDS finding that women are disproportionately affected, likely because they are the primary demographic seeking GLP-1 drugs for obesity treatment outside of traditional diabetes management.
The New Jersey and Pennsylvania data, drawn from the New Jersey Poison Control Center and the Children’s Hospital of Philadelphia (CHOP) Poison Control Center respectively, add further granularity. New Jersey’s 552% increase in just three years (29 cases in 2021 to 189 in 2024) is a dramatic escalation. CHOP’s data nearly doubled in a single year from 2023 to 2024, and the early 2025 figures suggest another record-breaking year is underway. The California CalPoison dataset — one of the most detailed state-level analyses publicly available — shows that of 1,047 cases from 2017 to 2023, 266 (25.4%) required hospitalization, with 14 reaching critical care. The fact that roughly 78% of California’s entire GLP-1 overdose caseload arrived after the FDA’s June 2021 Wegovy approval makes the causal relationship between mass-market prescription access and overdose risk impossible to ignore.
GLP-1 Overdose Causes and Compounded Drug Risk in the US 2026
PRIMARY CAUSES OF GLP-1 OVERDOSE IN THE US (2024–2025)
=======================================================
Therapeutic Error (took too soon / wrong dose)
▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓ ~80%
Compounded / DIY vial dosing errors
▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓ Significant subset
Intentional misuse (higher dose for faster weight loss)
▓▓▓▓▓▓▓ Documented; growing
Pediatric accidental exposure
▓▓▓▓ Rare but rising
FDA Adverse Events: Compounded Semaglutide & Tirzepatide
▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓ 1,150 reports (to Jul 31, 2025)
| Cause / Risk Factor | Data |
|---|---|
| Therapeutic errors as % of all NPDS cases (2017–2022) | 79.9% |
| FDA adverse event reports for compounded semaglutide & tirzepatide (to Jul 31, 2025) | 1,150 |
| FDA adverse event reports for compounded semaglutide alone (early 2025) | 455+ |
| FDA adverse event reports for compounded tirzepatide alone (early 2025) | 320+ |
| Documented compounded dose errors (patients taking 5–20x intended dose) | Yes — confirmed by FDA |
| Semaglutide shortage resolved (FDA) | February 2025 |
| Tirzepatide shortage resolved (FDA) | December 2024 |
| Compounded GLP-1s flagged as unapproved by FDA | Yes — ongoing enforcement |
| FDA-identified counterfeit Ozempic in US supply chain | Yes — confirmed |
| Reported compounded product containing semaglutide salt forms (sodium/acetate) | Yes — unverified safety |
| Most common overdose symptoms | Nausea, vomiting, abdominal pain, dizziness, headache |
| Typical duration of GLP-1 overdose symptoms | ~1 week (drug’s active window) |
Source: US Food and Drug Administration (FDA); National Poison Data System (NPDS), America’s Poison Centers
The single biggest driver of the GLP-1 overdose epidemic in the US is the compounded drug market. When FDA-approved semaglutide and tirzepatide faced severe national shortages between 2022 and early 2025, a wave of unregulated compounding pharmacies and online “telehealth” providers began selling non-FDA-approved versions of these drugs — typically as multi-dose vials requiring the patient to draw their own dose using a syringe. Unlike pre-filled, pre-measured injection pens, multi-dose vials require precise measurement, and patients — many with no prior injection experience — have repeatedly reported accidentally taking 5 to 20 times their intended dose simply by misreading measurement units on a syringe. The FDA had received 1,150 adverse event reports related to compounded semaglutide and tirzepatide as of July 31, 2025, a number the agency itself acknowledges vastly understates the actual total, because state-licensed pharmacies are not legally required to report adverse events to the FDA.
The compounded drug problem is compounded (no pun intended) by the presence of counterfeit Ozempic in the US drug supply chain — a fact the FDA has publicly confirmed. These products may contain the wrong ingredient, the wrong concentration, or no active ingredient at all, making every injection a gamble. The FDA resolved the semaglutide shortage in February 2025 and the tirzepatide shortage in December 2024, effectively cutting off the legal justification for large-scale compounding of these specific drugs. Yet enforcement timelines were contested in federal court by the Outsourcing Facilities Association, meaning compounded GLP-1 products continued to circulate well into 2026. Beyond compounding, poison centers consistently report that therapeutic errors by patients on FDA-approved drugs account for the largest share of calls — people taking doses too early, doubling up after believing a pen malfunctioned, or taking higher amounts deliberately to speed up weight loss. The 1,500% rise in poison control calls since 2019 cannot be attributed to compounding alone; it reflects a massive and rapidly growing patient population that is, in many cases, inadequately educated about the drugs they are injecting.
GLP-1 Overdose Hospitalization and Outcomes Data in the US 2026
GLP-1 OVERDOSE MEDICAL OUTCOMES — US DATA SUMMARY
==================================================
No / Mild Effect
▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓ 91.7%
Moderate Effect
▓▓▓▓ 8.0%
Major Effect
▓ 42 cases (NPDS 2017–2024)
Fatal
| 2 deaths (NPDS 2017–2024)
CA Hospitalization Rate
▓▓▓▓▓▓▓▓ 25.4% of cases
CA Critical Care Rate
▓ 5.3% of hospitalized cases
| Outcome Metric | Data |
|---|---|
| Cases with no or mild effects (NPDS 2017–2024) | 91.7% |
| Cases with moderate effects | 8.0% |
| Cases with major effects | 42 total cases |
| Total deaths (NPDS 2017–2024) | 2 |
| Cases evaluated in a healthcare facility (NPDS 2017–2022) | 22.4% |
| Cases admitted to critical care (NPDS 2017–2022) | 0.9% |
| Cases admitted to non-critical care | 4.1% |
| Serious medical outcomes (NPDS 2017–2022) | 6.2% |
| CA cases requiring hospitalization (CalPoison 2017–2023) | 266 of 1,047 (25.4%) |
| CA hospitalized cases requiring critical care | 14 (5.3% of hospitalized) |
| CA hospitalized cases discharged from ER | ~83% |
| Indiana cases not requiring healthcare facility (2025) | 73% |
| Increase in serious outcomes & HCF admissions (2021–2022) | 129.9% and 95.8% respectively |
| Duration of overdose symptoms | ~1 week (aligned with drug’s half-life) |
Source: National Poison Data System (NPDS), America’s Poison Centers; California Poison Control System (CalPoison); Indiana Poison Center
When looking at GLP-1 overdose hospitalization rates in the United States, the data presents a nuanced picture. On one hand, the headline figure of 91.7% of cases producing no or mild effects might suggest that most overdoses are manageable non-events. On the other hand, with 8,501 cases recorded nationally in 2024 alone, even that 8.3% with more serious outcomes translates to over 700 Americans experiencing moderate to major GLP-1 overdose effects in a single year — and that number grows every year. California’s CalPoison data offers a particularly sharp look at hospitalization: 25.4% of all GLP-1 exposure cases in California required hospitalization, a rate far higher than the national NPDS average, possibly reflecting more complete reporting or a higher share of compounded-drug-related cases in the state.
The 129.9% increase in serious medical outcomes between 2021 and 2022 — identified in the peer-reviewed NPDS analysis published in the Journal of Medical Toxicology — is one of the starkest data points in the entire dataset. In a single year, not only did the total case count jump by 80.9%, but the most severe cases grew at an even faster rate. This means that as prescription volumes climbed following the Wegovy approval, the complexity and severity of overdose presentations was also escalating — a double compounding effect. Clinicians have noted that GLP-1 overdose symptoms can persist for approximately one week because the drugs are designed to be long-acting, maintaining therapeutic levels in the body for days after injection. This prolonged symptom window means that patients who overdose cannot simply wait a few hours for the drug to clear their system — they may face days of severe nausea, vomiting, abdominal pain, and in serious cases, hypoglycemia that requires clinical management.
GLP-1 Prescription Growth and Overdose Correlation in the US 2026
GLP-1 PRESCRIPTION GROWTH vs OVERDOSE CASE GROWTH (US)
=======================================================
PRESCRIPTIONS (% of adults, weight loss indication):
2019 |▓▓ | <3%
2024 |▓▓▓▓▓▓▓▓ | ~11.2% with obesity Rx
2026 |▓▓▓▓▓▓▓▓▓▓▓▓▓ | ~13%
POISON CONTROL CASES (national):
2019 |▓▓ | ~500 (baseline)
2022 |▓▓▓▓▓▓▓ | 2,170
2024 |▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓ | 8,501
| Metric | Year | Figure |
|---|---|---|
| GLP-1 prescriptions for weight loss (share of all adults) | 2021 | <3% |
| GLP-1 prescriptions for weight loss (share of all adults) | 2026 | ~13% |
| Adults with obesity/overweight prescribed GLP-1 (2024) | 2024 | 11.2% |
| Adults with type 2 diabetes using GLP-1 injectables (2024) | 2024 | 26.5% |
| GLP-1 prescriptions for ages 18–39, growth (2019–2024) | 2019–2024 | +588% |
| Bariatric surgery rate change (2019–2024) | 2019–2024 | –42% |
| GLP-1 market value globally (2022) | 2022 | $22.4 billion |
| GLP-1 poison control cases (2020) | 2020 | 1,090 |
| GLP-1 poison control cases (2024) | 2024 | 8,501 |
| GLP-1 poison control calls growth (2019–2026) | 2019–2026 | ~1,500% |
| GLP-1 exposure rate per million (2017) | 2017 | 0.97 |
| GLP-1 exposure rate per million (2024) | 2024 | 18.79 |
Source: Epic Research (prescription growth); CDC National Health Interview Survey 2024 (NHIS); National Poison Data System (NPDS); FAIR Health; HealthVerity Marketplace
The relationship between GLP-1 prescription growth and overdose incidence in the US is not coincidental — it is causal and direct. Between 2021 and 2026, GLP-1 prescriptions for weight loss quadrupled from under 3% to approximately 13% of adults, according to Epic Research. Over that same period, poison control cases jumped from roughly 1,500 annually to over 8,500 in 2024 alone, with 2025 annualizing well above that. The 588% increase in GLP-1 prescriptions among adults aged 18–39 between 2019 and 2024 is particularly significant because younger adults may have less experience self-administering injectable medications and less access to consistent medical follow-up, making dosing errors more likely. Meanwhile, the 42% decline in bariatric surgeries over the same period confirms that GLP-1 drugs are actively replacing a more medically supervised intervention — meaning patients who would previously have been closely monitored through a surgical program are now managing a complex injectable drug regimen with far less clinical oversight.
The CDC’s 2024 National Health Interview Survey (NHIS) data provides additional context: 26.5% of all US adults with diagnosed type 2 diabetes were using GLP-1 injectables in 2024, with the highest use rates among Hispanic adults (31.3%) and those aged 50–64 (33.3%). This scale of use — concentrated among populations who may have complex comorbidities and polypharmacy situations — amplifies the risk of inadvertent dosing errors and drug interactions. As the number of Americans taking these medications continues to climb toward what some analysts project will be one in eight US adults by the end of the decade, the GLP-1 overdose burden on US poison control systems, emergency departments, and hospitals is structurally set to rise unless comprehensive patient education, secure medication storage mandates, and tighter oversight of online prescribing platforms are implemented at scale.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
